Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · November 12, 2022

Nivolumab in Combination With Chemoradiotherapy for Intermediate- and High-Risk Locally Advanced HNSCC

International Journal of Radiation Oncology, Biology, Physics


Additional Info

Disclosure statements are available on the authors' profiles:

International Journal of Radiation Oncology, Biology, Physics
Safety of nivolumab added to chemoradiotherapy platforms for intermediate and high-risk local-regionally advanced head and neck squamous cell carcinoma: RTOG Foundation 3504
Int. J. Radiat. Oncol. Biol. Phys 2022 Oct 10;[EPub Ahead of Print], ML Gillison, RL Ferris, J Harris, AD Colevas, LK Mell, C Kong, RC Jordan, KL Moore, MT Truong, C Kirsch, A Chakravarti, DM Blakaj, DA Clump, JP Ohr, JF Deeken, MF Gensheimer, NF Saba, JA Dorth, DI Rosenthal, RS Leidner, RJ Kimple, M Machtay, WJ Curran, P Torres-Saavedra, QT Le

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading